{
    "clinical_study": {
        "@rank": "16744", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Cannabidiol 200mg Oral", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cannabidiol 400mg Oral", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Cannabidiol 800mg Oral", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this trial is to investigate a novel treatment for cannabis dependence:\n      cannabidiol. Between 96 and 168 young people who want to quit cannabis and meet criteria for\n      moderate cannabis use disorder (DSM-5) will be recruited from the community. Stage one aims\n      to identify the Most Effective Dose (MEDmg) of oral cannabidiol for reducing cannabis use\n      over four treatment weeks. Stage two will determine whether the MED identified in stage 1\n      can offer an effective treatment for cannabis dependence."
        }, 
        "brief_title": "Cannabidiol: a Novel Intervention for Cannabis Use Problems?", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Cannabis Use Disorder", 
        "condition_browse": {
            "mesh_term": "Marijuana Abuse"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged between 16 and 60 years old.\n\n          -  Meet DSM-5 criteria for moderate cannabis use disorder (\u22654 DSM-5 criteria)\n\n          -  Express desire to quit using cannabis within the next four weeks,\n\n          -  Have \u22651 previous failed quit attempt.\n\n          -  Smoke tobacco with cannabis,\n\n          -  Test positive for recent cannabis use according to urine analysis,\n\n          -  Vital signs within healthy limits and have capacity to give consent\n\n        Exclusion Criteria:\n\n          -  Not willing to use effective contraception from when consent is taken to 6 weeks\n             after treatment has stopped\n\n          -  Positive pregnancy test or breastfeeding\n\n          -  Allergies to the Investigational Medicinal Product (IMP) or placebo and its\n             excipients\n\n          -  >twice/month use of other illicit drugs\n\n          -  Outside normal Body Mass Index (BMI)\n\n          -  A physical health problem deemed clinically significant\n\n          -  The use of current prescribed psychotropic drugs\n\n          -  Current or prior self-reported diagnosis of a psychotic disorder\n\n          -  Non-English speakers due to verbal assessments."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "16 Years"
        }, 
        "enrollment": {
            "#text": "168", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02044809", 
            "org_study_id": "12/0278"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cannabidiol 200mg Oral", 
                    "Cannabidiol 400mg Oral", 
                    "Cannabidiol 800mg Oral"
                ], 
                "intervention_name": "Cannabidiol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "last_name": "Valerie Curran, BA MA PhD DClinPsy"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom"
                }, 
                "name": "Clinical Psychopharmacology Unit"
            }, 
            "investigator": {
                "last_name": "Valerie Curran, BA MA PhD DClinPsy", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase IIa/b, Randomised, Double-blind, Placebo-controlled, Single-site, Parallel Group Clinical Trial to Examine Cannabidiol (CBD) as a Pharmacological Treatment for Cannabis Dependence.", 
        "overall_contact": {
            "email": "v.curran@ucl.ac.uk", 
            "last_name": "Valerie Curran, BA MA PhD DClinPsy"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: Research Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "This study has two stages. This is the primary endpoint criteria for stage 1.", 
                "measure": "Urinary 11-nor-9-Carboxy-delta-9-tetrahydrocannabinol:creatinine (THC-COOH:creatinine)", 
                "safety_issue": "No", 
                "time_frame": "up to 4 weeks"
            }, 
            {
                "description": "This study has two stages. This is the primary endpoint criteria for stage 1.", 
                "measure": "Number of days abstinent from cannabis", 
                "safety_issue": "No", 
                "time_frame": "up to 4 weeks"
            }, 
            {
                "description": "This study has two stages. This is the primary endpoint criteria for stage 2.", 
                "measure": "Diagnostic and Statistical Manual- 5 (DSM-5) criteria for moderate cannabis dependence", 
                "safety_issue": "No", 
                "time_frame": "up to 4 weeks"
            }, 
            {
                "description": "This study has two stages. This is the primary endpoint criteria for stage 2.", 
                "measure": "Urinary 11-nor-9-Carboxy-delta-9-tetrahydrocannabinol:creatinine(THC-COOH:creatinine) below 50ng/ml", 
                "safety_issue": "No", 
                "time_frame": "week 4"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02044809"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Psychological Wellbeing, Cognition and Endocannabinoids will be measured by questionnaire methods, neuropsychological testing and biological samples.", 
            "measure": "Psychological Wellbeing, Cognition and Endocannabinoids", 
            "safety_issue": "No", 
            "time_frame": "Up to 28 weeks"
        }, 
        "source": "University College, London", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University College, London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}